le Wilson, MD, one of the principal investigators in the clinical trial being conducted in the Flint area, summarized the design of the ongoing study in Michigan after presentations on the research described above. There also was general discussion of the safety profile of anatabine, the presumed mechanism of action, and ongoing clinical research. The third conference, held October 27 in Newport Beach, California, also summarized the research to date, the status of the ongoing human studies, and the emerging safety profile of Anatabloc™. Approximately 150 physicians and allied health practitioners from southern California attended this conference.
Curtis Wright, MD, MPH, Senior Medical Officer for Rock Creek Pharmaceuticals said, "The response to Anatabloc from the healthcare community has been quite positive, as evidenced by robust participation in question-and-answer sessions during the conferences. In addition, requests for samples, products and research support are increasing. The research presentations make clear that exciting potentials lie ahead as we continue to explore the relationship between anatabine and inflammation."
Certain statements in this press release other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "continues," "likely," "may," "opportunity," "potential," "projects," "will," "expects," "plans," "intends" and similar expressions to identify forward-looking statemenPage: 1 2 3 4 Related medicine technology :1
. First CyberKnife VSI System Installed at Creekside Cancer Care2
. Star Scientific Comments on Roskamp Institutes Plans to Conduct Human Alzheimers Clinical Trials Using a Compound (RCP-006) Developed by Rock Creek Pharmaceuticals, Inc.3
. Rock Creek Pharmaceuticals Discloses Filing of Provisional Patent Application For Isolated Anatabine Isomer4
. Swedish/Mill Creek Emergency Department, Ambulatory Care Center Opens Soon5
. Roskamp Institute Obtains IRB Approval for Multi-Site Human Clinical Trial with Rock Creek Pharmaceutical RCP-006 Compound6
. Rock Creek Pharmaceuticals Discloses Further Anatabine Patent Filing7
. Rock Creek Pharmaceuticals Offers International Shipping Options for Anatabloc™8
. Rock Creek Pharmaceuticals Announces Expanded International Shipping Options for Anatabloc™, Physician Conferences on Anatabine Research9
. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)10
. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML11
. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia